112 related articles for article (PubMed ID: 19289395)
21. [Her2/neu receptor: one of the basic factors rendering tailored therapy feasible in breast cancer patients].
Kulka J
Orv Hetil; 2005 Apr; 146(17):785-90. PubMed ID: 17918634
[TBL] [Abstract][Full Text] [Related]
22. What is the ideal HER2 test for Herceptin therapy?
Jpn J Clin Oncol; 2000 Apr; 30(4):208-9, 211. PubMed ID: 10830993
[No Abstract] [Full Text] [Related]
23. [Herceptin (trastuzumab)].
Yamashiro H; Toi M
Gan To Kagaku Ryoho; 2007 Aug; 34(8):1173-6. PubMed ID: 17687197
[TBL] [Abstract][Full Text] [Related]
24. Recent trends of HER-2 testing and trastuzumab therapy for breast cancer.
Kurosumi M
Breast Cancer; 2009; 16(4):284-7. PubMed ID: 19657709
[TBL] [Abstract][Full Text] [Related]
25. Breast cancer: the upgraded role of HER-3 and HER-4.
Karamouzis MV; Badra FA; Papavassiliou AG
Int J Biochem Cell Biol; 2007; 39(5):851-6. PubMed ID: 17254832
[TBL] [Abstract][Full Text] [Related]
26. Isolated tumor cells in breast cancer.
Sonke GS; Linn SC
N Engl J Med; 2009 Nov; 361(20):1995; author reply 1995-6. PubMed ID: 19911470
[No Abstract] [Full Text] [Related]
27. Trastuzumab after primary treatment for early stage HER2-positive breast cancer reduces recurrence.
Dent R; Clemons M
Cancer Treat Rev; 2006 Apr; 32(2):144-8. PubMed ID: 16517084
[No Abstract] [Full Text] [Related]
28. [Systemic pharmacotherapy in breast cancer].
Boér K
Orv Hetil; 2004 Jan; 145(4):187-92. PubMed ID: 14978885
[No Abstract] [Full Text] [Related]
29. Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer.
Roukos DH
J Clin Oncol; 2010 Jun; 28(17):e279-80; author reply e282-3. PubMed ID: 20406920
[No Abstract] [Full Text] [Related]
30. [Molecular targeted therapy for breast cancer treatment, challenge to cure].
Yamashiro H; Toi M
Nihon Rinsho; 2010 Oct; 68(10):1854-8. PubMed ID: 20954329
[TBL] [Abstract][Full Text] [Related]
31. [Predictive value of Her2/neu expression/amplification for the targeted treatment of breast cancer].
Lehr HA; Schaefer SC; Delaloye JF
Rev Med Suisse; 2009 Jul; 5(211):1525-9. PubMed ID: 19694364
[TBL] [Abstract][Full Text] [Related]
32. Trastuzumab in breast cancer.
Gilbert SG
N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16467555
[No Abstract] [Full Text] [Related]
33. [Herceptin].
Morginstin T; Shani S; Shemer J
Harefuah; 2000 Mar; 138(6):459-64. PubMed ID: 10883160
[No Abstract] [Full Text] [Related]
34. [Monoclonal antibodies as adjuvant breast cancer therapy. Tumor cells in continuing sleep?].
MMW Fortschr Med; 2001 Nov; 143(44):56. PubMed ID: 11732401
[No Abstract] [Full Text] [Related]
35. First MAb approved for treatment of metastatic breast cancer.
Brenner TL; Adams VR
J Am Pharm Assoc (Wash); 1999; 39(2):236-8. PubMed ID: 10079656
[No Abstract] [Full Text] [Related]
36. HER-2/neu expression in primary and metastatic breast cancer.
Lower EE; Glass E; Blau R; Harman S
Breast Cancer Res Treat; 2009 Jan; 113(2):301-6. PubMed ID: 18273700
[TBL] [Abstract][Full Text] [Related]
37. Targeting HER2 in the adjuvant setting: dealing with new standards and with open questions.
Smith IE
Breast; 2009 Oct; 18 Suppl 3():S146-9. PubMed ID: 19914535
[No Abstract] [Full Text] [Related]
38. New developments in adjuvant therapy for breast cancer.
Sledge GW
Clin Adv Hematol Oncol; 2005 Sep; 3(9):688-90. PubMed ID: 16224442
[No Abstract] [Full Text] [Related]
39. From the molecule to the clinic--inhibiting HER2 to treat breast cancer.
Eisenhauer EA
N Engl J Med; 2001 Mar; 344(11):841-2. PubMed ID: 11248162
[No Abstract] [Full Text] [Related]
40. HER2 testing, adjuvant trastuzumab use and results. Our experience in South Wales.
Webster R; Palaniappan N; Abraham J; Bertelli G; Jasani B; Barrett-Lee P
Clin Oncol (R Coll Radiol); 2010 Dec; 22(10):894. PubMed ID: 20708911
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
